Company profile
Tandem Diabetes Care, Inc.
NASDAQ: TNDM · Healthcare · Medical - Devices
#154 of 1,422 Healthcare companies by revenue53rd-percentile growth
EA Score
66BFH 55DQ 83GM 62SS 77
v0.1 · 65/100 weight · provisional
↑ workforce scale, market scale · ↓ return on equity, balance-sheet leverage
Methodology →Revenue TTM
$1.0B
Rev growth YoY (TTM)
-6.8%
Net income (FY)
-$204.7M
Employees
2,500
as of 2026-08-10
Market cap
$1.5B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.0B$1.0B2025
Net income-$204.7M-$204.7M2025
Operating income-$187.3M-$187.3M2025
Total assets$881.1M$881.1M2025
Liabilities$725.9M$725.9M2025
Equity$155.2M$155.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Supplies and Other54%
Pump46%
By geography
UNITED STATES70%
Non-US30%
The read
What is Tandem Diabetes Care, Inc.’s revenue?
Tandem Diabetes Care, Inc. booked $1.0B in FY2025 revenue, growing 7.9% year over year — about the middle of the pack among Healthcare companies we track, at a -20.2% net margin.
Peers · Healthcare
Embecta Corp.67BACADIA Pharmaceuticals Inc.82B+Bone Biologics Corporation45DWELL Health Technologies Corp.71BGuardant Health, Inc.65BClaritev Corporation61CNeighbors
San Diego →Key facts
CEOJohn F. Sheridan
SectorHealthcare
IndustryMedical - Devices
HeadquartersSan Diego, CA
ExchangeNASDAQ: TNDM
Employees2,500
IPO date2013-11-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.